Disclosed are novel crystalline forms of (S)-5-benzyl-N-(5-methyl-4-oxo-2,3,4,5-tetrahydrobenzo[b][1,4]oxazepin-3-yl)-4H-1,2,4-triazole-3-carboxamide, and solvates thereof and pharmaceutical compositions containing the same. Also disclosed are processes for the preparation thereof and methods for use thereof.

Provided is a novel compound having an excellent suppression effect against arrhythmia including atrial fibrillation and being useful as a pharmaceutical product without antiviral effect. Disclosed is a compound represented by the following General Formula (I), a pharmaceutically acceptable salt thereof, or a solvate thereof (in the formula, the dotted line portion represents a single bond or a double bond; R.sup.1 represents an optionally substituted C.sub.1-6 alkyl group; Q represents an oxygen atom, a sulfur atom, or NR.sup.5; R.sup.2 represents (C?O)R.sup.6, CHR.sup.6R.sup.7, or CH.sub.2OR.sup.8; and R.sup.3 and R.sup.4, which may be identical or different, each represent an amino group, an azide group, or XR.sup.9, with the proviso that any one of R.sup.3 and R.sup.4 is an amino group). ##STR00001##

Provided is a novel compound having an excellent suppression effect against arrhythmia including atrial fibrillation and being useful as a pharmaceutical product without antiviral effect. Disclosed is a compound represented by the following General Formula (I), a pharmaceutically acceptable salt thereof, or a solvate thereof (in the formula, the dotted line portion represents a single bond or a double bond; R.sup.1 represents an optionally substituted C.sub.1-6 alkyl group; Q represents an oxygen atom, a sulfur atom, or NR.sup.5; R.sup.2 represents (C?O)R.sup.6, CHR.sup.6R.sup.7, or CH.sub.2OR.sup.8; and R.sup.3 and R.sup.4, which may be identical or different, each represent an amino group, an azide group, or XR.sup.9, with the proviso that any one of R.sup.3 and R.sup.4 is an amino group). ##STR00001##

Disclosed are novel crystalline forms of (S)-5-benzyl-N-(5-methyl-4-oxo-2,3,4,5-tetrahydrobenzo[b][1,4]oxazepin-3-yl)-4H-1,2,4-triazole-3-carboxamide, and solvates thereof and pharmaceutical compositions containing the same. Also disclosed are processes for the preparation thereof and methods for use thereof.

Disclosed are novel crystalline forms of (S)-5-benzyl-N-(5-methyl-4-oxo-2,3,4,5-tetrahydrobenzo[b][1,4]oxazepin-3-yl)-4H-1,2,4-triazole-3-carboxamide, and solvates thereof and pharmaceutical compositions containing the same. Also disclosed are processes for the preparation thereof and methods for use thereof.

The invention relates to compounds that have an affinity to the -opioid receptor and the ORL 1-receptor, methods for their production, medications containing these compounds and the use of these compounds for the treatment of pain and other conditions.

The invention relates to compounds that have an affinity to the -opioid receptor and the ORL 1-receptor, methods for their production, medications containing these compounds and the use of these compounds for the treatment of pain and other conditions.

Provided is a novel compound having an excellent suppression effect against arrhythmia including atrial fibrillation and being useful as a pharmaceutical product without antiviral effect. Disclosed is a compound represented by the following General Formula (I), a pharmaceutically acceptable salt thereof, or a solvate thereof (in the formula, the dotted line portion represents a single bond or a double bond; R.sup.1 represents an optionally substituted C.sub.1-6 alkyl group; Q represents an oxygen atom, a sulfur atom, or NR.sup.5; R.sup.2 represents (CO)R.sup.6, CHR.sup.6R.sup.7, or CH.sub.2OR.sup.8; and R.sup.3 and R.sup.4, which may be identical or different, each represent an amino group, an azide group, or XR.sup.9, with the proviso that any one of R.sup.3 and R.sup.4 is an amino group).

##STR00001##

Provided is a novel compound having an excellent suppression effect against arrhythmia including atrial fibrillation and being useful as a pharmaceutical product without antiviral effect. Disclosed is a compound represented by the following General Formula (I), a pharmaceutically acceptable salt thereof, or a solvate thereof (in the formula, the dotted line portion represents a single bond or a double bond; R.sup.1 represents an optionally substituted C.sub.1-6 alkyl group; Q represents an oxygen atom, a sulfur atom, or NR.sup.5; R.sup.2 represents (CO)R.sup.6, CHR.sup.6R.sup.7, or CH.sub.2OR.sup.8; and R.sup.3 and R.sup.4, which may be identical or different, each represent an amino group, an azide group, or XR.sup.9, with the proviso that any one of R.sup.3 and R.sup.4 is an amino group).

##STR00001##